Regulation of the stem‑like properties of estrogen receptor‑positive breast cancer cells through NR2E3/NR2C2 signaling

Xie,Shanglun; Hu,Yaru; Jin,Jiacheng; Fu,Lingzhi; Zhang,Cong; Yang,Qing; Niu,Yaxin; Sheng,Zhiyong

doi:10.3892/etm.2023.12173

Regulation of the stem‑like properties of estrogen receptor‑positive breast cancer cells through NR2E3/NR2C2 signaling

Authors:
- Shanglun Xie
- Yaru Hu
- Jiacheng Jin
- Lingzhi Fu
- Cong Zhang
- Qing Yang
- Yaxin Niu
- Zhiyong Sheng
View Affiliations

Affiliations: School of Life Sciences, Anhui Province Key Laboratory of Translational Cancer Research, Bengbu Medical College, Bengbu, Anhui 233030, P.R. China, Department of Ophthalmology, Fuyang People's Hospital, Fuyang, Anhui 236000, P.R. China, School of Life Sciences, Anhui Province Key Laboratory of Translational Cancer Research, Bengbu Medical College, Bengbu, Anhui 233030, P.R. China, Department of Ophthalmology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233099, P.R. China
Published online on: August 22, 2023 https://doi.org/10.3892/etm.2023.12173
Article Number: 474
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer stem cells (CSCs) are major drivers of metastasis, drug resistance and recurrence in numerous cancers. However, critical factors that can modulate CSC stemness have not been clearly identified. Nuclear receptor subfamily 2 group E member 3 (nr2e3) expression has been previously reported to be positively associated with drug sensitivity and favorable clinical outcomes in patients with estrogen receptor (ER)⁺ breast cancer. This suggests that nr2e3 expression may be inversely associated with CSC stemness in this type of tumor cells. The present study aimed to investigate the regulatory roles of NR2E3 in the stem‑like properties of ER⁺ breast cancer cells and to identify the underlying mechanisms. Bioinformatics analysis was performed using the data derived from the Cancer Genome Atlas database. Nr2e3‑specific shRNA and nuclear receptor subfamily 2 group C member 2 (nr2c2) overexpressed plasmids were constructed to silence and enhance the expression of nr2e3 and nr2c2, respectively. Transwell and wound healing experiments were conducted to evaluate the migration and invasion ability of MCF7 cells, while colony formation tests were used to evaluate the clonality. Flow cytometry was used to detect the percentage of CD44⁺CD24^‑/low cells. Reverse transcription‑quantitative PCR and western blotting were performed to detect expression at the mRNA and protein levels. The results showed that compared with normal breast tissues and MCF10A cells, the expression of nr2e3 was increased in ER⁺ breast tumor tissues and cell lines. Nr2e3 silencing promoted the migration, invasion and colony‑forming ability of the ER⁺ MCF7 cells. It also increased the expression of epithelial‑mesenchymal transition markers and stem cell‑related transcription factors, in addition to the percentage of CD44⁺CD24^‑/low cells. The expression of nr2e3 and nr2c2 was found to be positively correlated. Nr2e3 knockdown decreased the mRNA and protein expression levels of nr2c2, whereas nr2c2 overexpression reversed the elevated CD44⁺CD24^‑/low cell ratio and the increased migratory activity caused by nr2e3 silencing. The results of the present study suggest that NR2E3 may serve an important role in modulating the stem‑like properties of ER⁺ breast cancer cells, where NR2E3/NR2C2 signaling may be a therapeutic target in ER⁺ breast cancer.

View Figures

View References

1	Aísa-Marín I, López-Iniesta MJ, Milla S, Lillo J, Navarro G, de la Villa P and Marfany G: Nr2e3 functional domain ablation by CRISPR-Cas9D10A identifies a new isoform and generates retinitis pigmentosa and enhanced S-cone syndrome models. Neurobiol Dis. 146(105122)2020.PubMed/NCBI View Article : Google Scholar
2	Li S, Datta S, Brabbit E, Love Z, Woytowicz V, Flattery K, Capri J, Yao K, Wu S, Imboden M, et al: Nr2e3 is a genetic modifier that rescues retinal degeneration and promotes homeostasis in multiple models of retinitis pigmentosa. Gene Ther. 28:223–241. 2021.PubMed/NCBI View Article : Google Scholar
3	Khanal T, Leung YK, Jiang W, Timchenko N, Ho SM and Kim K: NR2E3 is a key component in p53 activation by regulating a long noncoding RNA DINO in acute liver injuries. FASEB J. 33:8335–8348. 2019.PubMed/NCBI View Article : Google Scholar
4	Garattini E, Bolis M, Paroni G, Fratelli M and Terao M: Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeutic targets in breast-cancer. Oncotarget. 7:42661–42682. 2016.PubMed/NCBI View Article : Google Scholar
5	Park YY, Kim K, Kim SB, Hennessy BT, Kim SM, Park ES, Lim JY, Li J, Lu YL, Gonzalez-Angulo AM, et al: Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. EMBO Mol Med. 4:52–67. 2012.PubMed/NCBI View Article : Google Scholar
6	Zhao Z, Wang L and Xu W: IL-13Rα2 mediates PNR-induced migration and metastasis in ERα-negative breast cancer. Oncogene. 34:1596–1607. 2015.PubMed/NCBI View Article : Google Scholar
7	Bracci PM, Zhou M, Young S and Wiemels J: Serum autoantibodies to pancreatic cancer antigens as biomarkers of pancreatic cancer in a San Francisco Bay Area case-control study. Cancer. 118:5384–5394. 2012.PubMed/NCBI View Article : Google Scholar
8	Eichen JG, Dalmau J, Demopoulos A, Wade D, Posner JB and Rosenfeld M: The photoreceptor cell-specific nuclear receptor is an autoantigen of paraneoplastic retinopathy. J Neuroophthalmol. 21:168–172. 2001.PubMed/NCBI View Article : Google Scholar
9	Khanal T, Choi K, Leung YK, Wang J, Kim D, Janakiram V, Cho SG, Puga A, Ho SM and Kim K: Loss of NR2E3 represses AHR by LSD1 reprogramming, is associated with poor prognosis in liver cancer. Sci Rep. 7(10662)2017.PubMed/NCBI View Article : Google Scholar
10	Zhang L, Chen W, Liu S and Chen C: Targeting breast cancer stem cells. Int J Biol Sci. 19:552–570. 2023.PubMed/NCBI View Article : Google Scholar
11	Taurin S and Alkhalifa H: Breast cancers, mammary stem cells, and cancer stem cells, characteristics, and hypotheses. Neoplasia. 22:663–678. 2020.PubMed/NCBI View Article : Google Scholar
12	Lim JR, Mouawad J, Gorton OK, Bubb WA and Kwan AH: Cancer stem cell characteristics and their potential as therapeutic targets. Med Oncol. 38(76)2021.PubMed/NCBI View Article : Google Scholar
13	Rahmati M, Johari B, Kadivar M, Rismani E and Mortazavi Y: Suppressing the metastatic properties of the breast cancer cells using STAT3 decoy oligodeoxynucleotides: A promising approach for eradication of cancer cells by differentiation therapy. J Cell Physiol. 235:5429–5444. 2020.PubMed/NCBI View Article : Google Scholar
14	Johari B, Rahmati M, Nasehi L, Mortazavi Y, Faghfoori MH and Rezaeejam H: Evaluation of STAT3 decoy oligodeoxynucleotides' synergistic effects on radiation and/or chemotherapy in metastatic breast cancer cell line. Cell Biol Int. 44:2499–2511. 2020.PubMed/NCBI View Article : Google Scholar
15	Johari B and Moradi M: Application of transcription factor decoy oligodeoxynucleotides (ODNs) for cancer therapy. Methods Mol Biol. 2521:207–230. 2022.PubMed/NCBI View Article : Google Scholar
16	Bai X, Ni J, Beretov J, Graham P and Li Y: Cancer stem cell in breast cancer therapeutic resistance. Cancer Treat Rev. 69:152–163. 2018.PubMed/NCBI View Article : Google Scholar
17	Muscat GEO, Eriksson NA, Byth K, Loi S, Graham D, Jindal S, Davis MJ, Clyne C, Funder JW, Simpson ER, et al: Research resource: Nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. Mol Endocrinol. 27:350–365. 2013.PubMed/NCBI View Article : Google Scholar
18	Xie S, Han S, Qu Z, Liu F, Li J, Yu S, Reilly J, Tu J, Liu X, Lu Z, et al: Knockout of Nr2e3 prevents rod photoreceptor differentiation and leads to selective L-/M-cone photoreceptor degeneration in zebrafish. Biochim Biophys Acta Mol Basis Dis. 1865:1273–1283. 2019.PubMed/NCBI View Article : Google Scholar
19	Wang W, Zhang L, Wang Y, Ding Y, Chen T, Wang Y, Wang H, Li Y, Duan K, Chen S, et al: Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer. Cell Death Dis. 8(e3071)2017.PubMed/NCBI View Article : Google Scholar
20	Yan Y, Liu F, Han L, Zhao L, Chen J, Olopade OL, He M and Wei M: HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. J Exp Clin Cancer Res. 37(256)2018.PubMed/NCBI View Article : Google Scholar
21	Gooding AJ and Schiemann WP: Epithelial-mesenchymal transition programs and cancer stem cell phenotypes: Mediators of breast cancer therapy resistance. Mol Cancer Res. 18:1257–1270. 2020.PubMed/NCBI View Article : Google Scholar
22	Recouvreux MV, Moldenhauer MR, Galenkamp KMO, Jung M, James B, Zhang Y, Lowy A, Bagchi A and Commisso C: Glutamine depletion regulates Slug to promote EMT and metastasis in pancreatic cancer. J Exp Med. 217(e20200388)2020.PubMed/NCBI View Article : Google Scholar
23	Venturini G, Kokona D, Steiner BL, Bulla EG, Jovanovic J, Zinkernagel MS and Escher P: In vivo analysis of onset and progression of retinal degeneration in the Nr2e3rd7/rd7 mouse model of enhanced S-cone sensitivity syndrome. Sci Rep. 11(19032)2021.PubMed/NCBI View Article : Google Scholar
24	Choi MY, Romer AI, Hu M, Lepourcelet M, Mechoor A, Yesilaltay A, Krieger M, Gray PA and Shivdasaniet RA: A dynamic expression survey identifies transcription factors relevant in mouse digestive tract development. Development. 133:4119–4129. 2006.PubMed/NCBI View Article : Google Scholar
25	Nishimura M, Naito S and Yokoi T: Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab Pharmacokinet. 19:135–149. 2004.PubMed/NCBI View Article : Google Scholar
26	Cai X, Conley SM, Cheng T, Al-Ubaidi MR and Naash MI: A 350 bp region of the proximal promoter of Rds drives cell-type specific gene expression. Exp Eye Res. 91:186–194. 2010.PubMed/NCBI View Article : Google Scholar
27	Wen Z, Pyeon D, Wang Y, Lambert P, Xu W and Ahlquist P: Orphan nuclear receptor PNR/NR2E3 stimulates p53 functions by enhancing p53 acetylation. Mol Cell Biol. 32:26–35. 2012.PubMed/NCBI View Article : Google Scholar
28	Garancher A, Lin CY, Morabito M, Richer W, Rocques N, Larcher M, Bihannic L, Smith K, Miquel C, Leboucher S, et al: NRL and CRX define photoreceptor identity and reveal subgroup-specific dependencies in medulloblastoma. Cancer Cell. 33:435–449.e6. 2018.PubMed/NCBI View Article : Google Scholar
29	Al-Khuzaei S, Broadgate S, Halford S, Jolly JK, Shanks M, Clouston P and Downes SM: Novel pathogenic sequence variants in NR2E3 and clinical findings in three patients. Genes (Basel). 11(1288)2020.PubMed/NCBI View Article : Google Scholar
30	Khanal T, Kim D, Johnson A, Choubey D and Kim K: Deregulation of NR2E3, an orphan nuclear receptor, by benzo(a)pyrene-induced oxidative stress is associated with histone modification status change of the estrogen receptor gene promoter. Toxicol Lett. 237:228–236. 2015.PubMed/NCBI View Article : Google Scholar
31	Lin SJ, Yang DR, Yang G, Lin CY, Chang HC, Li G and Chang C: TR2 and TR4 orphan nuclear receptors: An overview. Curr Top Dev Biol. 125:357–373. 2017.PubMed/NCBI View Article : Google Scholar
32	Haider NB, Mollema N, Gaule M, Yuan Y, Sachs AJ, Nystuen AM, Naggert JK and Nishina PM: Nr2e3-directed transcriptional regulation of genes involved in photoreceptor development and cell-type specific phototransduction. Exp Eye Res. 89:365–372. 2009.PubMed/NCBI View Article : Google Scholar
33	Roduit R, Escher P and Schorderet DF: Mutations in the DNA-binding domain of NR2E3 affect in vivo dimerization and interaction with CRX. PLoS One. 4(e7379)2009.PubMed/NCBI View Article : Google Scholar
34	Yao X, Zhang Y, Wu L, Cheng R, Li C, Qu C and Ji H: Immunohistochemical study of NR2C2, BTG2, TBX19, and CDK2 expression in 31 paired primary/recurrent nonfunctioning pituitary adenomas. Int J Endocrinol. 2019(5731639)2019.PubMed/NCBI View Article : Google Scholar
35	Zhang L, Zhang J, Ma Y, Chen J, Dong B, Zhao W, Wang X, Zheng Q, Fang F and Yang Y: Testicular orphan receptor 4 (TR4) is a marker for metastasis and poor prognosis in non-small cell lung cancer that drives the EMT phenotype. Lung Cancer. 89:320–328. 2015.PubMed/NCBI View Article : Google Scholar
36	Qiu X, Zhu J, Sun Y, Fan K, Yang DR, Li G, Yang G and Chang C: TR4 nuclear receptor increases prostate cancer invasion via decreasing the miR-373-3p expression to alter TGFβR2/p-Smad3 signals. Oncotarget. 6:15397–15409. 2015.PubMed/NCBI View Article : Google Scholar
37	Fan Z, Zheng J, Xue Y, Liu X, Wang D, Yang C, Ma J, Liu L, Ruan X, Wang Z and Liu Y: NR2C2-uORF targeting UCA1-miR-627-5p-NR2C2 feedback loop to regulate the malignant behaviors of glioma cells. Cell Death Dis. 9(1165)2018.PubMed/NCBI View Article : Google Scholar
38	Ren W, Hu J, Li H, Chen J, Ding J, Zu X and Fan B: miR-616-5p promotes invasion and migration of bladder cancer via downregulating NR2C2 expression. Front Oncol. 11(762946)2021.PubMed/NCBI View Article : Google Scholar
39	Jin R, Lin H, Li G, Xu J, Shi L, Chang C and Cai X: TR4 nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression. Cell Death Dis. 9(283)2018.PubMed/NCBI View Article : Google Scholar
40	Shyr CR, Hu YC, Kim E and Chang C: Modulation of estrogen receptor-mediated transactivation by orphan receptor TR4 in MCF-7 cells. J Biol Chem. 277:14622–14628. 2002.PubMed/NCBI View Article : Google Scholar
41	Gervin E, Shin B, Opperman R, Cullen M, Feser R, Maiti S and Majumder M: Chemically induced hypoxia enhances miRNA functions in breast cancer. Cancers (Basel). 12(2008)2020.PubMed/NCBI View Article : Google Scholar
42	Yang SF, Hou MF, Chen FM, Ou-Yang F, Wu YC, Chai CY and Yeh YT: Prognostic value of protein inhibitor of activated STAT3 in breast cancer patients receiving hormone therapy. BMC Cancer. 16(20)2016.PubMed/NCBI View Article : Google Scholar
43	Lei JT, Gou X, Seker S and Ellis MJ: ESR1 alterations and metastasis in estrogen receptor positive breast cancer. J Cancer Metastasis Treat. 5(38)2019.PubMed/NCBI View Article : Google Scholar
44	Matutino A, Joy AA, Brezden-Masley C, Chia S and Verma S: Hormone receptor-positive, HER2-negative metastatic breast cancer: Redrawing the lines. Curr Oncol. 25 (Suppl 1):S131–S141. 2018.PubMed/NCBI View Article : Google Scholar